The aim of this letter is to focus on the survival of patients treated with nivolumab and cabozantinib according to prior first-line TKI. We used data from CheckMate 025 and METEOR for a subsequent subgroup analysis
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis / Roviello G; Generali D. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 72:(2017), pp. 1027-1028. [10.1016/j.eururo.2017.07.019]
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis
Roviello G;
2017
Abstract
The aim of this letter is to focus on the survival of patients treated with nivolumab and cabozantinib according to prior first-line TKI. We used data from CheckMate 025 and METEOR for a subsequent subgroup analysis
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Roviello G, TKI MRCC treated with Nivolumab or Cabozantinib.pdf
Accesso chiuso
Dimensione
432.36 kB
Formato
Adobe PDF
|
432.36 kB | Adobe PDF | Richiedi una copia |
|
Roviello European Urology.pdf
Accesso chiuso
Dimensione
366.71 kB
Formato
Adobe PDF
|
366.71 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
